Indegene stock gets listed at a premium of around 46%

13 May 2024 , 10:03 AM

Indegene shares got listed today at a premium. The IPO shares debuted at ₹655 on the NSE, reflecting a premium of 44.95% over the issue price of ₹452, and at ₹659 on the BSE, commanding a premium of 45.95%.

During the subscription period from May 6 to May 8, investor enthusiasm drove the issue to be oversubscribed by an impressive 69.91 times. This translated to a total of 201.81 Crore equity shares being bought against the 2.88 Crore shares on offer. Notably, high net worth individuals (non-institutional investors) led the charge, subscribing to the reserved portion by a staggering 55.07 times. Qualified institutional buyers (QIBs) followed suit, subscribing 197.55 times their allocated portion, while retail investors also showed strong interest, booking their portion 7.95 times.

The public offer, valued at ₹1,841.76 Crore, comprised a combination of a fresh issue of shares worth ₹760 Crore and an offer-for-sale of 2.39 Crore shares valued at ₹1,081.76 Crore. The price band was set at ₹430-452 per share.

Indegene specializes in assisting pharmaceutical companies across various facets including drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and sales and marketing of their products.